{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intron-A&page=7",
    "query": {
      "intervention": "Intron-A",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 158,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intron-A&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intron-A&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T12:09:26.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00402428",
      "title": "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "albumin interferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1331,
      "start_date": "2006-12",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-08",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402428"
    },
    {
      "nct_id": "NCT00026221",
      "title": "Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Recombinant Interferon Alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2001-11",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-03-17",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026221"
    },
    {
      "nct_id": "NCT00015652",
      "title": "Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": null,
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00015652"
    },
    {
      "nct_id": "NCT04418219",
      "title": "Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Recurrent Breast Carcinoma",
        "Refractory Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Interferon Alpha 2b-like Protein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality of Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2020-12-21",
      "completion_date": "2024-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418219"
    },
    {
      "nct_id": "NCT00036569",
      "title": "A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "pegylated interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 32,
      "start_date": "2002-05",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2012-02-13",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036569"
    },
    {
      "nct_id": "NCT00791271",
      "title": "Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alpha-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2008-09-02",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791271"
    },
    {
      "nct_id": "NCT04349410",
      "title": "The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "CoVid 19 Positive"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine, Azithromycin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Clindamycin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Clindamycin, Primaquine - low dose.",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine, Clindamycin, Primaquine - high dose.",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Interferon-Alpha2B",
          "type": "DRUG"
        },
        {
          "name": "Losartan",
          "type": "DRUG"
        },
        {
          "name": "Convalescent Serum",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Camelot Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1800,
      "start_date": "2020-04-11",
      "completion_date": "2020-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-11-12",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04349410"
    },
    {
      "nct_id": "NCT04379518",
      "title": "Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Symptomatic COVID-19 Infection Laboratory-Confirmed"
      ],
      "interventions": [
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2020-11-17",
      "completion_date": "2023-03-15",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379518"
    },
    {
      "nct_id": "NCT00004088",
      "title": "Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "pamidronate disodium",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 77,
      "start_date": "1999-04-13",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-02",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Duarte, California",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004088"
    },
    {
      "nct_id": "NCT01939847",
      "title": "IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Treatment suggestion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2013-09-19",
      "completion_date": "2017-02-01",
      "has_results": false,
      "last_update_posted_date": "2019-02-28",
      "last_synced_at": "2026-10-23T12:09:26.503Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01939847"
    }
  ]
}